| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics, Inc. (VIRX) has 0 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. VIRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2022 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,655 | $4.02 | $14,679.21 | -4.2% | |
| Aug 26, 2022 | Royston Ivor | CEO &President | Sale+OE | 13,379 | $4.01 | $53,656.48 | -2.1% | |
| May 26, 2022 | Royston Ivor | CEO &President | Sale+OE | 13,162 | $1.90 | $25,022.28 | -2.1% | |
| May 26, 2022 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 2,154 | $1.90 | $4,094.97 | -4.9% | |
| May 26, 2022 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,596 | $1.90 | $6,836.36 | -4.3% | |
| Feb 28, 2022 | Royston Ivor | CEO &President | Sale+OE | 14,635 | $2.78 | $40,677.98 | -2.4% | |
| Feb 28, 2022 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 2,395 | $2.78 | $6,656.90 | -5.6% | |
| Feb 28, 2022 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,998 | $2.78 | $11,112.44 | -5.0% | |
| Nov 29, 2021 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 4,541 | $4.81 | $21,847.46 | -5.4% | |
| Nov 29, 2021 | Chevallard Daniel R. | CFO And COO | Sale+OE | 7,579 | $4.81 | $36,463.76 | -4.8% |